Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double blind, parallel, placebo controlled, drug-drug interaction study to investigate the safety, tolerability and pharmacokinetics of multiple doses of HTL0018318 given alone and in combination with donepezil at steady state in elderly volunteers.

Next Previous
X
Search
Trial Profile

A randomised, double blind, parallel, placebo controlled, drug-drug interaction study to investigate the safety, tolerability and pharmacokinetics of multiple doses of HTL0018318 given alone and in combination with donepezil at steady state in elderly volunteers.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jul 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HTL 18318 (Primary) ; Donepezil
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Heptares Therapeutics

    • Most Recent Events

    • 23 Jun 2021 Results assessing the safety and tolerability and pharmacokinetics of repeated doses of HTL0018318 (15 or 25 mg) given without and in combination with donepezil, published in the Drugs in R and D.
    • 05 Aug 2017 Status changed from not yet recruiting to completed.
    • 23 Feb 2017 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top